Literature DB >> 18509007

Predicting values of lipids and white blood cell count for all-site cancer in type 2 diabetes.

Xilin Yang1, Wing-Yee So, Ronald C W Ma, Gary T C Ko, Alice P S Kong, Qingsheng Wang, Clive S Cockram, Chun-Chung Chow, Juliana C N Chan, Peter C Y Tong.   

Abstract

Type 2 diabetic patients have increased cancer risk. We developed and validated an all-site cancer risk score in a prospective cohort of 7374 Chinese type 2 diabetic patients free of known history of cancer at enrolment, using split-half validation. Spline Cox model was used to detect common risk factors of cancer and to guide linear transformation of non-linear risk factors. After a median follow-up period of 5.45 years, 365 patients (4.95%) developed cancer. Body mass index (BMI; <24.0 or > or =27.6 kg/m2), triglyceride (> or =0.81 to <1.41 mmol/l), high-density lipoprotein cholesterol (<0.9 or > or =1.8 mmol/l), total cholesterol (<4.3 mmol/l) and white blood cell (WBC) count (<5.8x10(9) count per litre) were associated with increased cancer risks and exhibited non-linear relationships. We further linear transformed these terms for selection using backward Cox regression (P<0.05 for stay) in the training dataset. In the test dataset, calibration was checked using Hosmer-Lemeshow test and discrimination checked using area under receiver operating characteristic curve. In addition to age and current smoking, only linear-transformed total cholesterol and WBC count were selected. The risk score was 0.0488xage (years)-0.5810xtotal cholesterol (mmol/l, coded to 4.3 if >4.3)-0.3596xWBC count (10(9) counts/l, 5.8 if >5.8)+0.6390xcurrent smoking status (1 if yes). The 5-year probability of cancer was 1-0.9590(EXP(0.9382x(RISK SCORE+1.5903))). The predicted cancer probability was not significantly different from the observed cancer probability during the 5-year follow-up. The adjusted area under receiver operating characteristic curve was 0.712. In conclusion, BMI, lipids and WBC count have predicting values for cancer.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18509007     DOI: 10.1677/ERC-07-0266

Source DB:  PubMed          Journal:  Endocr Relat Cancer        ISSN: 1351-0088            Impact factor:   5.678


  17 in total

1.  Diabetes, insulin and cancer risk.

Authors:  Xi-Lin Yang; Juliana Cn Chan
Journal:  World J Diabetes       Date:  2012-04-15

2.  Metformin and the risk of cancer in type 2 diabetes: methodological challenges and perspectives.

Authors:  Xilin Yang; Juliana Cn Chan
Journal:  Ann Transl Med       Date:  2014-06

3.  Blood pressure and all-cause mortality among patients with type 2 diabetes.

Authors:  Weiqin Li; Peter T Katzmarzyk; Ronald Horswell; Yujie Wang; Jolene Johnson; Gang Hu
Journal:  Int J Cardiol       Date:  2016-01-07       Impact factor: 4.164

Review 4.  Drug-subphenotype interactions for cancer in type 2 diabetes mellitus.

Authors:  Xilin Yang; Heung M Lee; Juliana C N Chan
Journal:  Nat Rev Endocrinol       Date:  2015-03-24       Impact factor: 43.330

5.  Low LDL cholesterol, albuminuria, and statins for the risk of cancer in type 2 diabetes: the Hong Kong diabetes registry.

Authors:  Xilin Yang; Wing Yee So; Ronald C W Ma; Gary T C Ko; Alice P S Kong; Hailu Zhao; Andrea O Y Luk; Christopher W K Lam; Chung Shun Ho; Peter C Y Tong; Juliana C N Chan
Journal:  Diabetes Care       Date:  2009-07-10       Impact factor: 19.112

6.  Associations of hyperglycemia and insulin usage with the risk of cancer in type 2 diabetes: the Hong Kong diabetes registry.

Authors:  Xilin Yang; Gary T C Ko; Wing Yee So; Ronald C W Ma; Linda W L Yu; Alice P S Kong; Hailu Zhao; Chun-Chung Chow; Peter C Y Tong; Juliana C N Chan
Journal:  Diabetes       Date:  2010-02-25       Impact factor: 9.461

7.  Hyperglycemia and duration of diabetes as risk factors for abnormal lipids: a cross sectional survey of 19,757 patients with type 2 diabetes in China.

Authors:  Linong Ji; Jianping Weng; Juming Lu; Xiaohui Guo; Wenying Yang; Weiping Jia; Dajin Zou; Zhiguang Zhou; Dalong Zhu; Qiuhe Ji; Lixin Shi; Xilin Yang
Journal:  J Endocrinol Invest       Date:  2014-06-25       Impact factor: 4.256

8.  Methodological challenges to control for immortal time bias in addressing drug effects in type 2 diabetes.

Authors:  Xi-Lin Yang; Xiao-Xu Huo; Juliana Cn Chan
Journal:  World J Methodol       Date:  2015-09-26

9.  Low HDL cholesterol, metformin use, and cancer risk in type 2 diabetes: the Hong Kong Diabetes Registry.

Authors:  Xilin Yang; Wing Yee So; Ronald C W Ma; Alice P S Kong; Heung Man Lee; Linda W L Yu; Chun-Chung Chow; Risa Ozaki; Gary T C Ko; Juliana C N Chan
Journal:  Diabetes Care       Date:  2010-10-27       Impact factor: 19.112

10.  Additive interaction between the renin-angiotensin system and lipid metabolism for cancer in type 2 diabetes.

Authors:  Xilin Yang; Hailu Zhao; Yi Sui; Ronald C W Ma; Wing Yee So; Gary T C Ko; Alice P S Kong; Risa Ozaki; Chun Yip Yeung; Gang Xu; Peter C Y Tong; Juliana C N Chan
Journal:  Diabetes       Date:  2009-04-28       Impact factor: 9.461

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.